CN109310672B - σ受体配体在癌症中的用途 - Google Patents

σ受体配体在癌症中的用途 Download PDF

Info

Publication number
CN109310672B
CN109310672B CN201780034885.9A CN201780034885A CN109310672B CN 109310672 B CN109310672 B CN 109310672B CN 201780034885 A CN201780034885 A CN 201780034885A CN 109310672 B CN109310672 B CN 109310672B
Authority
CN
China
Prior art keywords
substituted
yloxy
compound
pyrazol
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780034885.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109310672A (zh
Inventor
丹尼尔·扎马尼罗-卡斯塔涅多
乔斯-卡洛斯·普拉多斯-萨拉萨尔
塞瓦斯蒂亚·魏地拉-塞斯
乔斯-米格尔·韦拉埃尔南德斯
卡洛斯-拉蒙·普拉塔-萨拉曼
霍尔迪·布鲁纳-埃斯库埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of CN109310672A publication Critical patent/CN109310672A/zh
Application granted granted Critical
Publication of CN109310672B publication Critical patent/CN109310672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780034885.9A 2016-06-06 2017-06-05 σ受体配体在癌症中的用途 Active CN109310672B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382258 2016-06-06
EP16382258.8 2016-06-06
PCT/EP2017/063614 WO2017211763A1 (en) 2016-06-06 2017-06-05 Use of sigma receptor ligands in cancer

Publications (2)

Publication Number Publication Date
CN109310672A CN109310672A (zh) 2019-02-05
CN109310672B true CN109310672B (zh) 2022-05-03

Family

ID=56134287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034885.9A Active CN109310672B (zh) 2016-06-06 2017-06-05 σ受体配体在癌症中的用途

Country Status (8)

Country Link
US (1) US20190142840A1 (enExample)
EP (1) EP3463339B1 (enExample)
JP (1) JP7094231B2 (enExample)
CN (1) CN109310672B (enExample)
AR (1) AR108682A1 (enExample)
ES (1) ES2969815T3 (enExample)
TW (1) TW201808300A (enExample)
WO (1) WO2017211763A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128309A1 (en) * 2009-05-08 2010-11-11 Modern Biosciences, Plc. Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole
CN102497864A (zh) * 2009-08-14 2012-06-13 埃斯特韦实验室有限公司 用于预防或治疗由化疗诱发的疼痛的σ配体
CN102985089A (zh) * 2010-05-21 2013-03-20 埃斯特韦实验室有限公司 预防和/或治疗化学疗法或放射疗法引起的呕吐的σ配体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696199B2 (en) * 2004-08-27 2010-04-13 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
PH12012501027A1 (en) 2009-11-25 2022-04-01 Esteve Labor Dr 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
HUE029738T2 (en) 2010-02-04 2017-04-28 Esteve Labor Dr 4- [2 - [[5-Methyl-1- (2-naphthalenyl) -1H-pyrazol-3-yl] oxy] ethyl] morpholine hydrochloride polymorphs and solvates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128309A1 (en) * 2009-05-08 2010-11-11 Modern Biosciences, Plc. Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole
CN102497864A (zh) * 2009-08-14 2012-06-13 埃斯特韦实验室有限公司 用于预防或治疗由化疗诱发的疼痛的σ配体
CN102985089A (zh) * 2010-05-21 2013-03-20 埃斯特韦实验室有限公司 预防和/或治疗化学疗法或放射疗法引起的呕吐的σ配体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization;L Romero等;《Br J Pharmacol》;20121231;第166卷(第8期);2289-2306 *
Potential applications for sigma receptor ligands in cancer diagnosis and therapy;Arenvan Waarde等;《Biochimica et Biophysica Acta (BBA) - Biomembranes》;20151231;第1848卷(第10期);2703-2714 *

Also Published As

Publication number Publication date
EP3463339C0 (en) 2023-12-06
TW201808300A (zh) 2018-03-16
WO2017211763A1 (en) 2017-12-14
CN109310672A (zh) 2019-02-05
EP3463339B1 (en) 2023-12-06
JP7094231B2 (ja) 2022-07-01
JP2019517572A (ja) 2019-06-24
AR108682A1 (es) 2018-09-12
US20190142840A1 (en) 2019-05-16
EP3463339A1 (en) 2019-04-10
ES2969815T3 (es) 2024-05-22

Similar Documents

Publication Publication Date Title
CN101861151B (zh) 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗
US20170157134A1 (en) Combination therapy
US20070248672A1 (en) Indole and Azaindole Derivatives with Antitumor Action
JP2018531983A (ja) タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
CN106474127A (zh) 用于治疗增生性疾病的2‑甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合
CN109789127A (zh) 吲哚啉酮化合物的用途
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
US20240245704A1 (en) Pharmaceutical composition and use of multi-kinase inhibitor
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
CN109310672B (zh) σ受体配体在癌症中的用途
JP6445082B2 (ja) ５’−ヒドロキシ−５−ニトロ−インジルビン−３’−オキシムを有効成分として含有する乳がん治療剤
CN108721279B (zh) 包含5′-羟基-5-硝基-靛玉红-3′-肟作为活性成分的乳腺癌治疗剂
WO2014038894A1 (ko) 에틸(2-메틸-3{(E)-[(나프타[2,1-b]퓨란-2-일카보닐)하이드라조노]메틸}-1H-인돌-1-일)아세테이트, 이의 유사체를 유효성분으로 포함하는 암 예방 및 치료용 조성물
JP7637064B2 (ja) 癌細胞成長抑制効果を示す新規なヘテロ環置換ピリミジン誘導体及びそれを含む薬剤学的組成物
KR102347516B1 (ko) Ｐａｒｐ 저해용 화합물 및 이의 의약 용도
WO2019176985A1 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
HK40065706A (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
HK40065706B (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
HK40066075A (zh) 一种含有tsl-1502m的药物组合物及其应用
HK40066075B (zh) 一种含有tsl-1502m的药物组合物及其应用
AU2015256266A1 (en) BH4 antagonists and methods related thereto
WO2019230679A1 (ja) 抗腫瘍剤及び腫瘍治療方法
TW201825092A (zh) 使用包含吲哚嗪并[6, 7-b]吲哚衍生物的醫藥組合物或組合治療小細胞肺癌的方法
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant